טוען...
Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...
שמור ב:
| Main Authors: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI AG
2020-03-01
|
| סדרה: | International Journal of Molecular Sciences |
| נושאים: | |
| גישה מקוונת: | https://www.mdpi.com/1422-0067/21/7/2275 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|